Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 4244  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (796 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed2066    
    Printed31    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
LETTER TO EDITOR
Year : 2015  |  Volume : 63  |  Issue : 6  |  Page : 986-988

Transverse myelitis in a patient with primary antiphospholipid syndrome


Department of Medicine, Division of Neurology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

Date of Web Publication20-Nov-2015

Correspondence Address:
Waseem Raja Dar
Department of Medicine, Division of Neurology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.170077

Rights and Permissions



How to cite this article:
Dar WR, Dar IA, Sofi NU, Arshad F, Hussain M. Transverse myelitis in a patient with primary antiphospholipid syndrome. Neurol India 2015;63:986-8

How to cite this URL:
Dar WR, Dar IA, Sofi NU, Arshad F, Hussain M. Transverse myelitis in a patient with primary antiphospholipid syndrome. Neurol India [serial online] 2015 [cited 2020 Sep 30];63:986-8. Available from: http://www.neurologyindia.com/text.asp?2015/63/6/986/170077


Sir,

The manifestations of antiphospholipid antibody syndrome (aPS) are diverse. The neurological manifestations may range from simple headaches to the more devastating phenomena such as stroke. Transverse myelitis (TM) is very rare in aPS, more so in the primary aPS. Further, presently there are no clear guidelines for the management of TM in aPS. The outcome in these patients can be devastating if the treatment is delayed. We present the case of an adult woman, a known case of aPS for 23 years, who developed paraparesis. Her magnetic resonance imaging (MRI) showed features typical of TM. A brief review of literature follows.

A 56-year-old woman, a tourist from Italy, had a significant history of primary aPS syndrome. She presented with progressive asymmetrical weakness that began 7 days prior to her admission. She reported difficulty in walking, numbness in the body below her breasts, and urinary incontinence. Physical examination revealed moderate-to-severe paraparesis with bilateral extensor plantar responses, brisk reflexes in both lower limbs associated with impairment of all sensations and a sensory level at T4-T5. Her magnetic resonance imaging (MRI) revealed a lower cervical and upper thoracic cord lesion that showed enhancement after gadolinium administration, a finding consistent with TM [Figure 1] and [Figure 2].
Figure 1: Hyperintense signals in lower cervical and upper thoracic spinalcord from C4-T2 on contrast enhanced MRI of the spine

Click here to view
Figure 2: Hyperintense signal in the cord

Click here to view


The patient was managed with methylprednisolone pulse (MP) therapy for 5 days and low molecular weight heparin (LMWH). She improved after treatment with recovery of power in her lower limbs and improvement in sensations. She was discharged on hydroxychloroquine and oral steroids.

TM is the common designation for an acutely evolving inflammatory-demyelinative lesion of the spinal cord characterized by an acute or a subacute motor, sensory, and autonomic (bladder, bowel, and sexual) spinal cord dysfunction. The list of ailments that may be considered in the differential diagnosis of acute TM is fairly long [Table 1].
Table 1: Causes of Acute Transverse Myelitis

Click here to view


The patients present with either symmetric or asymmetric paraparesis/plegia, ascending paresthesias, loss of deep sensibility in the feet, a sensory level on the trunk, sphincteric dysfunction, and bilateral Babinski's sign.

aPS is a disorder that manifests clinically as recurrent venous or arterial thrombosis and/or with recurrent abortions. Central nervous system (CNS) involvement is common in patients with antiphospholipid (Hughes) syndrome [Table 2]. In 1983, Hughes, in his original description of the syndrome, stressed on the importance of cerebral features in these patients.[1]
Table 2: Neurological manifestations of APLA syndrome

Click here to view


Although the mechanism of neurological involvement in patients with aPS is thought to be thrombotic in origin, many of the central nervous system manifestations cannot be explained solely by the hypercoagulability theory and probably have more complex underlying mechanisms.[2]

TM is a rare complication of aPS syndrome, reported in only 0.4% of the patients. It is particularly rare in primary aPS.[3],[4],[5] It was first described by Hughes in 1985 in a 45-year-old woman who developed TM over a 1-year period.[6] Serological tests suggested a lupus-like illness. IgM antibodies to cardiolipin were detected in high titers in her serum. Several of the aPS patients with TM have recurrent episodes. The exact pathogenesis of TM in aPS patients is not known and is thought to involve both ischemic episodes as well as anticardiolipin (aCL) antibody-mediated interactions. A strong association between aCL antibodies and TM in patients of aPS was described by Lavalle et al., who reported 10 out of 12 patients with TM and systemic lupus erythematosus (SLE) having aCL antibodies.[7] Kovacs et al., evaluated 14 patients with SLE and TM and 91 additional cases published in the English and German literature.[8] They found the incidence of TM in aPS to be 2% and TM occurring as the initial manifestation of SLE in a rather high number of patients (39% of the total patient population). In 42% of the total patient population analyzed, TM presented within the first 5 years of the diagnosis of SLE. The prominent presentation of TM in SLE seems to be a sensory level, predominantly in the thoracic area. Of the 64 of a total of 105 patients tested for antiphospholipid antibodies (aPL), 64% patients were found to be positive for them.

As TM in SLE is a very rare clinical manifestation, no definitive treatment guidelines have been instituted. Different treatment options available include methylprednisolone (MP) therapy, intravenous cyclophosphamide, and plasmapheresis. It has been postulated that an aggressive treatment instituted early in the course of the disease is crucial for a favorable response.[9]

Kovacs et al., found that treatment with intravenous MP alone led to a significant recovery. However, the use of intravenous MP followed by intravenous cyclophosphamide pulse (CP) seemed to be more effective than intravenous MP alone. Additional treatment with plasmapheresis in patients who did not improve with intravenous MP and intravenous CP did not seem to improve the outcome any further. Barile et al., found that cyclophosphamide was more effective than MP in the treatment of acute, severe neuropsychiatric manifestations of SLE that were associated with TM.[10]

Mok et al., used mycophenolate mofetil (MMF) in patients with SLE with TM and reported only a modest efficacy.[11] Two of their three patients responded partially to MMF, and their myelopathy relapsed while receiving the maintenance treatment. The authors recommended that adminstration of MMF in lupus myelopathy should be restricted to those patients who are either refractory/intolerant to or are reluctant to receive cyclophosphamide.

TM is a rare manifestation of aPS syndrome, and is even rarer in primary aPS. Early diagnosis and treatment are important for an optimal outcome. The combination of MP with intravenous cyclophosphamide is a better choice than steroids alone.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983;287:1088-9.  Back to cited text no. 1
[PUBMED]    
2.
Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181-9.  Back to cited text no. 2
    
3.
Kim JH, Lee SI, Park SI, Yoo WH. Recurrent transverse myelitis in primary antiphospholipid syndrome – Case report and literature review. Rheumatol Int 2004;24:244-6.  Back to cited text no. 3
    
4.
Shaharao V, Bartakke S, Muranjan MN, Bavdekar MS, Bavdekar SB, Udani VP. Recurrent acute transverse myelopathy: Association with antiphospholipid antibody syndrome. Indian J Pediatr 2004;71:559-61.  Back to cited text no. 4
    
5.
Lee DM, Jeon HS, Yoo WH. Transverse myelitis in a patient with primary antiphospholipid syndrome. Yonsei Med J 2003;44:323-7.  Back to cited text no. 5
    
6.
Harris EN, Gharavi AE, Mackworth-Young CG, Patel BM, Derue G, Hughes GR. Lupoid sclerosis: A possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis 1985;44:281-3.  Back to cited text no. 6
[PUBMED]    
7.
Lavalle C, Pizarro S, Drenkard C, Sánchez-Guerrero J, Alarcón-Segovia D. Transverse myelitis: A manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990;17:34-7.  Back to cited text no. 7
    
8.
Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: An analysis of 14 cases and review of the literature. Ann Rheum Dis 2000;59:120-4.  Back to cited text no. 8
    
9.
Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: Better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol 1995;242:326-31.  Back to cited text no. 9
    
10.
Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005;64:620-5.  Back to cited text no. 10
    
11.
Mok CC, Mak A, To CH. Mycophenolate mofetil for lupus related myelopathy. Ann Rheum Dis 2006;65:971-3.  Back to cited text no. 11
[PUBMED]    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow